LAS, a novel selective estrogen receptor modulator with chemopreventive and therapeutic activity in the N-nitroso-N-methylurea-induced rat mammary tumor model

Leonard A. Cohen, Brian Pittman, Chung Xiou Wang, César Aliaga, Li Yu, James D. Moyer

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

The N-nitroso-N-methylurea-induced rat mammary tumor model was used to conduct two types of studies: a prevention study designed to test the ability of the novel selective estrogen receptor modulator lasofoxifene (LAS) to inhibit the development of mammary tumors, and a treatment study designed to test the inhibitory effect of LAS on the growth of established tumors. The prevention study indicated that LAS markedly delayed the emergence of N-nitroso-N-methylurea-induced tumors to an extent similar to that obtained by the established antiestrogen tamoxifen (TAM). At the highest dose administered, both TAM and LAS reduced tumor incidence by 75% and total tumor number by 90% relative to the controls. LAS also reduced the multiplicity of tumors, i.e., the mean number of tumors per rat, and resulted in substantially smaller total tumor burden. In the treatment study, LAS significantly inhibited tumor growth compared with the controls. In addition, whereas none of the untreated tumors regressed completely over the experimental period, 40% of LAS-treated tumors regressed by >50% at the highest dose (10 mg/kg daily). The results of this study in a rat mammary tumor model indicate that LAS has both chemopreventive and chemotherapeutic effects quantitatively comparable with those of TAM.

Original languageEnglish (US)
Pages (from-to)8683-8688
Number of pages6
JournalCancer Research
Volume61
Issue number24
StatePublished - Dec 15 2001

Fingerprint

Selective Estrogen Receptor Modulators
Breast Neoplasms
Neoplasms
Tamoxifen
Therapeutics
Lasofoxifene
methylurea
Estrogen Receptor Modulators
Growth
Tumor Burden

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Cohen, Leonard A. ; Pittman, Brian ; Wang, Chung Xiou ; Aliaga, César ; Yu, Li ; Moyer, James D. / LAS, a novel selective estrogen receptor modulator with chemopreventive and therapeutic activity in the N-nitroso-N-methylurea-induced rat mammary tumor model. In: Cancer Research. 2001 ; Vol. 61, No. 24. pp. 8683-8688.
@article{a4b5de6b046b4414920ba9ffec4fc888,
title = "LAS, a novel selective estrogen receptor modulator with chemopreventive and therapeutic activity in the N-nitroso-N-methylurea-induced rat mammary tumor model",
abstract = "The N-nitroso-N-methylurea-induced rat mammary tumor model was used to conduct two types of studies: a prevention study designed to test the ability of the novel selective estrogen receptor modulator lasofoxifene (LAS) to inhibit the development of mammary tumors, and a treatment study designed to test the inhibitory effect of LAS on the growth of established tumors. The prevention study indicated that LAS markedly delayed the emergence of N-nitroso-N-methylurea-induced tumors to an extent similar to that obtained by the established antiestrogen tamoxifen (TAM). At the highest dose administered, both TAM and LAS reduced tumor incidence by 75{\%} and total tumor number by 90{\%} relative to the controls. LAS also reduced the multiplicity of tumors, i.e., the mean number of tumors per rat, and resulted in substantially smaller total tumor burden. In the treatment study, LAS significantly inhibited tumor growth compared with the controls. In addition, whereas none of the untreated tumors regressed completely over the experimental period, 40{\%} of LAS-treated tumors regressed by >50{\%} at the highest dose (10 mg/kg daily). The results of this study in a rat mammary tumor model indicate that LAS has both chemopreventive and chemotherapeutic effects quantitatively comparable with those of TAM.",
author = "Cohen, {Leonard A.} and Brian Pittman and Wang, {Chung Xiou} and C{\'e}sar Aliaga and Li Yu and Moyer, {James D.}",
year = "2001",
month = "12",
day = "15",
language = "English (US)",
volume = "61",
pages = "8683--8688",
journal = "Cancer Research",
issn = "0008-5472",
number = "24",

}

LAS, a novel selective estrogen receptor modulator with chemopreventive and therapeutic activity in the N-nitroso-N-methylurea-induced rat mammary tumor model. / Cohen, Leonard A.; Pittman, Brian; Wang, Chung Xiou; Aliaga, César; Yu, Li; Moyer, James D.

In: Cancer Research, Vol. 61, No. 24, 15.12.2001, p. 8683-8688.

Research output: Contribution to journalArticle

TY - JOUR

T1 - LAS, a novel selective estrogen receptor modulator with chemopreventive and therapeutic activity in the N-nitroso-N-methylurea-induced rat mammary tumor model

AU - Cohen, Leonard A.

AU - Pittman, Brian

AU - Wang, Chung Xiou

AU - Aliaga, César

AU - Yu, Li

AU - Moyer, James D.

PY - 2001/12/15

Y1 - 2001/12/15

N2 - The N-nitroso-N-methylurea-induced rat mammary tumor model was used to conduct two types of studies: a prevention study designed to test the ability of the novel selective estrogen receptor modulator lasofoxifene (LAS) to inhibit the development of mammary tumors, and a treatment study designed to test the inhibitory effect of LAS on the growth of established tumors. The prevention study indicated that LAS markedly delayed the emergence of N-nitroso-N-methylurea-induced tumors to an extent similar to that obtained by the established antiestrogen tamoxifen (TAM). At the highest dose administered, both TAM and LAS reduced tumor incidence by 75% and total tumor number by 90% relative to the controls. LAS also reduced the multiplicity of tumors, i.e., the mean number of tumors per rat, and resulted in substantially smaller total tumor burden. In the treatment study, LAS significantly inhibited tumor growth compared with the controls. In addition, whereas none of the untreated tumors regressed completely over the experimental period, 40% of LAS-treated tumors regressed by >50% at the highest dose (10 mg/kg daily). The results of this study in a rat mammary tumor model indicate that LAS has both chemopreventive and chemotherapeutic effects quantitatively comparable with those of TAM.

AB - The N-nitroso-N-methylurea-induced rat mammary tumor model was used to conduct two types of studies: a prevention study designed to test the ability of the novel selective estrogen receptor modulator lasofoxifene (LAS) to inhibit the development of mammary tumors, and a treatment study designed to test the inhibitory effect of LAS on the growth of established tumors. The prevention study indicated that LAS markedly delayed the emergence of N-nitroso-N-methylurea-induced tumors to an extent similar to that obtained by the established antiestrogen tamoxifen (TAM). At the highest dose administered, both TAM and LAS reduced tumor incidence by 75% and total tumor number by 90% relative to the controls. LAS also reduced the multiplicity of tumors, i.e., the mean number of tumors per rat, and resulted in substantially smaller total tumor burden. In the treatment study, LAS significantly inhibited tumor growth compared with the controls. In addition, whereas none of the untreated tumors regressed completely over the experimental period, 40% of LAS-treated tumors regressed by >50% at the highest dose (10 mg/kg daily). The results of this study in a rat mammary tumor model indicate that LAS has both chemopreventive and chemotherapeutic effects quantitatively comparable with those of TAM.

UR - http://www.scopus.com/inward/record.url?scp=0035893734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035893734&partnerID=8YFLogxK

M3 - Article

C2 - 11751385

AN - SCOPUS:0035893734

VL - 61

SP - 8683

EP - 8688

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 24

ER -